All Stories

  1. Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib

    Article • Journal of Clinical Medicine, March 2026, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  2. Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine

    Article • Journal of Clinical Medicine, February 2026, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  3. Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone

    Article • Journal of Clinical Medicine, January 2026, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  4. The Evolving Role of Second- and Third-Generation Tyrosine Kinase Inhibitors in Gastrointestinal Malignancies: Advances in Targeted Therapy with Sunitinib, Regorafenib, and Avapritinib

    Article • Journal of Clinical Medicine, January 2026, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  5. Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF–MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib

    Article • Journal of Clinical Medicine, November 2025, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  6. Targeted Therapies Modulating Mesenchymal–Epithelial Transition-Linked Oncogenic Signaling in the Tumor Microenvironment: Comparative Profiling of Capmatinib, Bemcentinib, and Galunisertib

    Article • Journal of Clinical Medicine, September 2025, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  7. Isotretinoin Treatment for Acne Vulgaris: A Five-Year Retrospective Analysis of Clinical and Biochemical Adverse Effects

    Article • Journal of Clinical Medicine, September 2025, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  8. Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma

    Article • Cancers, August 2025, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  9. Compliance with the European Pregnancy Prevention Programme in Isotretinoin Treatment: Safety Outcomes and Dose-Related Correlations

    Article • Journal of Clinical Medicine, May 2025, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  10. Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease

    Article • Journal of Clinical Medicine, April 2025, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  11. Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment

    Article • Journal of Clinical Medicine, March 2025, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  12. Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms

    Article • Biomedicines, October 2024, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  13. Epinephrine, Pregabalin, and Crizotinib as Three Medicines with Polish Implications over Three Last Centuries and in View of Three Different Drug Discovery Approaches

    Article • Biomedicines, September 2024, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  14. Unveiling a Dermatological Rarity: The Enigma of Vulvar Intraepithelial Neoplasia Grade III (HSIL) and the Role of p53 in Its Development

    Article • Biomedicines, August 2024, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  15. Structure–Activity Relationships and Therapeutic Applications of Retinoids in View of Potential Benefits from Drug Repurposing Process

    Article • Biomedicines, May 2024, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  16. Multivariate assessment of anticancer oleanane triterpenoids lipophilicity

    Article • Journal of Chromatography A, October 2021, Elsevier

    Dr. Habil. Pharm.D. Piotr Kawczak

  17. Chemometric analysis of bio-inspired micellar electrokinetic chromatographic systems – modelling of retention mechanism and prediction of biological properties using bile salts surfactants

    Article • Microchemical Journal, August 2021, Elsevier

    Dr. Habil. Pharm.D. Piotr Kawczak

  18. Assessment of blood–brain barrier permeability using micellar electrokinetic chromatography and P_VSA-like descriptors

    Article • Microchemical Journal, November 2020, Elsevier

    Dr. Habil. Pharm.D. Piotr Kawczak

  19. Drug affinity to human serum albumin prediction by retention of cetyltrimethylammonium bromide pseudostationary phase in micellar electrokinetic chromatography and chemically advanced template search descriptors

    Article • Journal of Pharmaceutical and Biomedical Analysis, September 2020, Elsevier

    Dr. Habil. Pharm.D. Piotr Kawczak

  20. Biopartitioning micellar electrokinetic chromatography – Concept study of cationic analytes

    Article • Microchemical Journal, May 2020, Elsevier

    Dr. Habil. Pharm.D. Piotr Kawczak

  21. Evaluation of Chemotherapeutic Activity of the Selected Bases’ Analogues of Nucleic Acids Supported by ab initio Various Quantum Chemical Calculations

    Article • Current Computer - Aided Drug Design, March 2020, Bentham Science Publishers

    Dr. Habil. Pharm.D. Piotr Kawczak

  22. QSAR Analysis of Selected Antimicrobial Structures Belonging to Nitro-derivatives of Heterocyclic Compounds

    Article • Letters in Drug Design & Discovery, February 2020, Bentham Science Publishers

    Dr. Habil. Pharm.D. Piotr Kawczak

  23. Lipophilicity Determination of Antifungal Isoxazolo[3,4-b]pyridin-3(1H)-ones and Their N1-Substituted Derivatives with Chromatographic and Computational Methods

    Article • Molecules, November 2019, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  24. Application of reversed-phase thin layer chromatography and QSRR modelling for prediction of protein binding of selected β-blockers

    Article • Journal of Pharmaceutical and Biomedical Analysis, November 2019, Elsevier

    Dr. Habil. Pharm.D. Piotr Kawczak

  25. Activity Evaluation and Selection of Some Classes of Antibiotics with the use of Semi-Empirical Quantum Mechanics and Quantitative Structure- Activity Relationships Approach

    Article • Combinatorial Chemistry & High Throughput Screening, June 2019, Bentham Science Publishers

    Dr. Habil. Pharm.D. Piotr Kawczak

  26. The comparison of semiempirical and ab initio molecular modeling methods in activity and property evaluation of selected antimicrobial sulfonamides

    Article • Medicinal Chemistry Research, March 2019, Springer Science + Business Media

    Dr. Habil. Pharm.D. Piotr Kawczak

  27. Study of the chromatographic behavior of selected antipsychotic drugs on RP-TLC based on quantitative structure–retention relationships

    Article • Journal of the Iranian Chemical Society, January 2019, Springer Science + Business Media

    Dr. Habil. Pharm.D. Piotr Kawczak

  28. Are the short cationic lipopeptides bacterial membrane disruptors? Structure-Activity Relationship and molecular dynamic evaluation

    Article • Biochimica et Biophysica Acta (BBA) - Biomembranes, January 2019, Elsevier

    Dr. Habil. Pharm.D. Piotr Kawczak

  29. Legal and economic identification and assessment of pharmacy substitution in narrow therapeutic index drugs, on the example of epileptic medications in Poland

    Article • Acta Poloniae Pharmaceutica - Drug Research, December 2018, Polish Pharmaceutical Society

    Dr. Habil. Pharm.D. Piotr Kawczak

  30. Application of QSAR Analysis and Different Quantum Chemical Calculation Methods in Activity Evaluation of Selected Fluoroquinolones

    Article • Combinatorial Chemistry & High Throughput Screening, November 2018, Bentham Science Publishers

    Dr. Habil. Pharm.D. Piotr Kawczak

  31. A policy view: gaps and weaknesses of substitution between biological products in law and economics dimension: the example of insulin

    Article • Acta Poloniae Pharmaceutica - Drug Research, August 2018, Polish Pharmaceutical Society

    Dr. Habil. Pharm.D. Piotr Kawczak

  32. Activity evaluation of some psychoactive drugs with the application of QSAR/QSPR modeling methods

    Article • Medicinal Chemistry Research, August 2018, Springer Science + Business Media

    Dr. Habil. Pharm.D. Piotr Kawczak

  33. Reversed-phase and normal-phase thin-layer chromatography and their application to the lipophilicity prediction of synthetic pyrethroids based on quantitative structure–retention relationships

    Article • JPC - Journal of Planar Chromatography - Modern TLC, April 2018, Akademiai Kiado

    Krzesimir Ciura, Dr. Habil. Pharm.D. Piotr Kawczak

  34. TLC and lipophilicity and QSRR.

    Article • Journal of Pharmaceutical and Biomedical Analysis, February 2018, Elsevier

    Dr. Habil. Pharm.D. Piotr Kawczak

  35. Characterization of antimicrobial and hemolytic properties of short synthetic cationic lipopeptides based on QSAR/QSTR approach

    Article • Amino Acids, December 2017, Springer Science + Business Media

    Dr. Habil. Pharm.D. Piotr Kawczak

  36. Cis-trans ismomerism of sulfonamides in application of QSRR method.

    Article • Current Pharmaceutical Analysis, December 2017, Bentham Science Publishers

    Dr. Habil. Pharm.D. Piotr Kawczak

  37. TLC and molecular descriptors.

    Article • Journal of Pharmaceutical and Biomedical Analysis, September 2017, Elsevier

    Dr. Habil. Pharm.D. Piotr Kawczak, Professor Michal J Markuszewski

  38. QSRR of antipsychotic drugs in TLC.

    Article • JPC - Journal of Planar Chromatography - Modern TLC, June 2017, Akademiai Kiado

    Krzesimir Ciura, Dr. Habil. Pharm.D. Piotr Kawczak

  39. Mass spectrometry in drug discovery

    Article • Medicinal Chemistry, June 2016, Bentham Science Publishers

    Dr. Habil. Pharm.D. Piotr Kawczak

  40. QSRR and steroid and phenentrene derivatives in TLC.

    Article • JPC - Journal of Planar Chromatography - Modern TLC, June 2016, Akademiai Kiado

    Krzesimir Ciura, Dr. Habil. Pharm.D. Piotr Kawczak, Professor Michal J Markuszewski

  41. QSRR of steroid hormones in TLC.

    Article • JPC - Journal of Planar Chromatography - Modern TLC, April 2016, Akademiai Kiado

    Krzesimir Ciura, Dr. Habil. Pharm.D. Piotr Kawczak, Professor Michal J Markuszewski

  42. QSRR/QSAR of macrolide antibiotics in TLC.

    Article • Monatshefte für Chemie - Chemical Monthly, December 2015, Springer Science + Business Media

    Dr. Habil. Pharm.D. Piotr Kawczak, Professor Michal J Markuszewski

  43. HPLC analysis of pesticides in double gradient.

    Article • May 2015, Taylor & Francis

    Dr. Habil. Pharm.D. Piotr Kawczak

  44. QSPR of adrenomimetics and adrenolytics.

    Article • Medicinal Chemistry Research, July 2014, Springer Science + Business Media

    Dr. Habil. Pharm.D. Piotr Kawczak

  45. QSAR analysis of local anesthetics.

    Article • Current Pharmaceutical Analysis, June 2014, Bentham Science Publishers

    Dr. Habil. Pharm.D. Piotr Kawczak

  46. QSAR analysis of selected drugs.

    Article • Combinatorial Chemistry & High Throughput Screening, August 2013, Bentham Science Publishers

    Dr. Habil. Pharm.D. Piotr Kawczak

  47. QSAR analysis of benzenosulfonamide derivatives.

    Article • Medicinal Chemistry, April 2013, Bentham Science Publishers

    Dr. Habil. Pharm.D. Piotr Kawczak

  48. QSAR and ANN analysis of imidazole derivatives.

    Article • Open Medicine, January 2013, De Gruyter

    Dr. Habil. Pharm.D. Piotr Kawczak

  49. QSAR/QSPR analysis of furane and thiophene amide derivatives.

    Article • International Journal of Molecular Sciences, May 2012, MDPI AG

    Dr. Habil. Pharm.D. Piotr Kawczak

  50. QSAR analysis of general anestethics.

    Article • Letters in Drug Design & Discovery, May 2012, Bentham Science Publishers

    Dr. Habil. Pharm.D. Piotr Kawczak

  51. QSAR/QSPR analysis of novel benzenosulfonamide derivatives.

    Article • Letters in Drug Design & Discovery, March 2012, Bentham Science Publishers

    Dr. Habil. Pharm.D. Piotr Kawczak

  52. Micellar Liquid Chromatography in pharmaceutical and biomedical analysis.

    Article • Open Chemistry, January 2012, De Gruyter

    Dr. Habil. Pharm.D. Piotr Kawczak

  53. Lipophilicity determination in MLC of new 1,3-purindiones.

    Article • Journal of Separation Science, April 2010, Wiley

    Dr. Habil. Pharm.D. Piotr Kawczak

  54. Purinediones.

    Article • Bioorganic & Medicinal Chemistry, November 2006, Elsevier

    Dr. Habil. Pharm.D. Piotr Kawczak

  55. Double gradient of organic modifier nad pKa in RP HPLC

    Article • Analytical Chemistry, January 2006, American Chemical Society (ACS)

    Dr Pawel Wiczling, Dr. Habil. Pharm.D. Piotr Kawczak